[1] Peyvandi, P., Peyvandi, H., & Amoozadeh, M. (2017). A New Synthesis for new Class of Opaque Compounds in Radiography. Applied Chemistry Today, 4(12), 46-50. (in Persian)
[2] Ghasemi, M. H., Kosari, E., Hosseinbeiki, M., Hosseini, S. K., & Shafiei, A. (2018). Applied Chemistry Today, 91-102. (in Persian)
[3] Rouhi, M., Asghari, S., & Ghanbarimasir, Z. (2024). Synthesis, biological investigation, and docking studies of benzimidazole derivatives as butyrylcholinesterase and acetylcholinesterase inhibitors. Applied Chemistry Today, 19(71), 247-266. (in Persian)
[4] Besharat, M., Arab-Salmanabadi, S., & Moradi, O. (2020). Synthesis and Characterization of a Three Rings Heterocyclic Spiro Furan and Evaluation of its Cytotoxicity Properties on G-292 Cell Lines. Applied Chemistry Today, 16(60), 25-36. (in Persian)
[5] Sabbaghzadeh, R., Moradi, M., Momeni-Moghadam, M., & Maleki, B. (2023). Evaluation of the results of chromen drug derivatives and their effect on colon cancer. Applied Chemistry Today, 18(67), 181-194. (in Persian)
[6] Labelle, M., Belley, M., Gareau, Y., Gauthier, JY., Guay, D., Gordon, R., Grossman, SG., Jones, TR., &
Leblanc, Y. (1995). Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme induction. Bioorg Med Chem Lett .5(3): 283-288.
[7] Schoors, DF., De-Smet, M., Reiss, T., Margolskee, D., Cheng, H., Larson, P., Amin, R., & Somers, G. Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. (1995). Br J Clin Pharmacol, 40(3): 277-280.
[8] Markham, A., & Faulds, D. Montelukast in the treatment of asthma and allergic rhinitis. (1998). Drugs ,56(2): 251-256.
[9] Noonan, MJ., Chervinsky, P., Brandon, M., Zhang, J., Kundu, S., Mcburney, J., & Reiss TF. (1998). Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J, 11(6): 1232-1239.
[10] Harrington, P. (2011). Development of an efficient and practical approach for the synthesis of Montelukast Sodium Intermediate. John Wiley & Sons, 6, 164−216.
[11] Young, R. (2012). Discovery and Development of Montelukast. John Wiley & Sons, 8, 154−195.
[12] Harrington, PJ., & Hoboken, NJ. (2011). Pharmaceutical Process Chemistry for Synthesis: Rethinking the Routes to Scale-Up. John Wiley & Sons, 164−216. (b) Young, R., Huang, X., Aslanian, R. G., Hoboken, NJ . (2012). In Case Studies in Modern Drug Discovery and Development. John Wiley & Sons, 154−195.
[13] Schilter, D,. & Bielawski, C. W. (2016). Synthesis of a 2,2-Dichloroimidazolidine-4,5-dione and its Application in a Chlorodehydroxylation, Organic Syntheses, 93, 413-421.
[14] Suri S, Sarin G. S., & Mahendru, M. (2006). A process for synthesizing diol (viii)-an intermediate of montelukast sodium. PCT Patent Application, 80(8), 3891-3901.
[15] Albaneze-Walker, J. E., Chen, Y., Humphrey, G., Krska, S., Tan, L., Itoh, T., Funane, S., Yokozawa, T., & Kobayashi, T. (2014). An Enantioselective Formal Synthesis of Montelukast Sodium. PCT Patent Application, 8, 3891-3901.
[16] Gao, Y., Liu, J., Guo, T., Xu, S., Zhu, H., Wei, F., Chen, S., Gebru, H., & Guo, H. (2018). Dichloroimidazolidinedione-Activated Beckmann Rearrangement of Ketoximes for Accessing Amides and Lactams. The Journal of Organic Chemistry, 83, 2040–2049.
[17] Saravanan, M., Satyanarayana, B., & Pratap-Reddy, B. (2013). New and Practical Synthesis of Montelukast Sodium, an Antiasthmatic Drug. Synthetic Communications, 43(15), 2050-2056.
